Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

Fig. 3

Cumulative events indicate the capacity of anti-CXCR3 (a,c) and anti-CXCR4 (b,d) antibody (ab) levels to predict deterioration in forced vital capacity (FVC) (a,b) and forced expiratory volume in 1 s (FEV1) (c,d) by ≥ 10% within 3 years of follow-up. P values (log-rank test) are given in Table 2. HR hazard ratio, 95-%-KI 95% confidence interval

Back to article page